AVXL Stock Forecast | Anavex Forecast 2023, 2024, 2025, 2030
Please disable Ad Blocker before you can visit the website !!!

AVXL Stock Forecast | Avanex Life Sciences Forecast 2023 – 2030

by Cavix   ·  December 3, 2022   ·  

Anavex Life Sciences studies are important for related diseases. AVXL stock is affected by this. A biopharmaceutical business in the trial stages is Anavex Life Sciences Corp. The company is working to create therapies that are specifically tailored to address neurodegenerative and neurodevelopmental problems.

Disorder, a rare severe neurological monogenic disorder brought on by abnormalities in the X-linked gene, methyl-CpG-binding enzyme 2, is one of the rare disorders that the company’s main chemical, ANAVEX2-73, is being developed to treat. Additionally, ANAVEX 3-71, ANAVEX 1-41, ANAVEX 1066, and ANAVEX 1037 are among its product prospects.

ANAVEX 3-71 is a potentially disease-modifying medication that can penetrate the central nervous and cure cognitive deficits. Sigma-1 agonist ANAVEX 1-41 is available. A combined sigma-1/sigma-2 ligand called ANAVEX 1066 is intended to possibly cure visceral and neuropathic pain. Pancreatic and prostate cancer are the two conditions that ANAVEX 1037 is intended to treat.

Yesterday, JonesTrading expert Soumit Roy reiterated a Buy rating and set a $80.00 price target on Anavex Life Sciences. Yesterday, the company’s shares were closed at $8.87. With an average selling price objective of $49.25, analysts currently rate Anavex Life Sciences as a Strong Buy, suggesting a potential upside of 455.24% from current prices.

Positive Outcomes Were Reported By The Biotech

As of 11:09 a.m. ET on Friday, shares of Anavex Life Sciences (AVXL stock 35.85%) were shooting 44.9% higher. The significant increase followed the company’s release of the findings from a stage 2b/3 clinical study assessing Anavex 2-73 for the treatment of early Alzheimer’s disease.

Clinical outcomes are almost always important triggers for biotech stock prices, whether they are positive or bad. This is particularly true for stocks of businesses that don’t yet have any products available on the market. Anavex is one such business. There are just two clinical-stage medicines in the biotech’s pipeline, and one of them is Anavex 2-73.

Both the primary and secondary study goals were satisfied by the oral Anavex 2-73 treatment, and patients who received it reported statistically significant improvements in cognition. According to Anavex, the president’s safety profile appeared to be fair.

Reaffirming A Buy Rating On Anavex Life Sciences, Berenberg Bank (AVXL)

Palomeque is an expert with a 32.14% success record and a market returns of -14.8%, according to TipRanks. Palomeque focuses on firms like Ascendis Pharma, Denali Therapeutics, and Anavex Life Sciences while covering the healthcare industry.

Strong Buy is the average analyst recommendation for Anavex Life Sciences, and the consensus price objective is $49.25, which would increase by 308.71%. BTIG reiterated its Buy rating on the company with just a $35.00 market valuation in a report published today.

According to Anavex Life Sciences’ most recent earnings report, the company posted a monthly GAAP net loss of $14.29 million in the quarter ending September 30. In contrast, the business reported a GAAP net loss of $11.72 million the previous year.

Regarding ANAVEX®2-73

In the evaluation of the Intent-to-Treat (ITT) group, the ANAVEX®2-73 therapy met the main goal and decreased clinical decline on the overall cognitive and behavioral scales over 48 weeks.

Patients with Alzheimer’s disease showed observable improvement after receiving ANAVEX®2-73. In comparison to patients on placebo, those receiving ANAVEX®2-73 were 84% more likely to experience improved cognition. As measured by an ADAS-Cog rating decrease of -0.50 points of better from beginning to treatment’s conclusion, odds ratio = 1.84.

Patients treated with ANAVEX®2-73 experienced an average ADAS-Cog cognition score improvement of -4.03 points. When compared to placebo, ANAVEX®2-73 therapy was 167% more probable to enhance function when the change in the ADCS-ADL score was +3.5 points or higher.

ANAVEX®2-73 Treatment

The Clinical Alzheimer’s Rating Scale Sum of Boxes was used to measure clinical decline in cognition and function. ANAVEX®2-73 treatment also met this secondary endpoint, with a treatment distinction in mean score transformation of -0.42 points or a 27% reduction in the ITT population, when compared to placebo.

Blarcamesine, also known as ANAVEX®2-73, was usually well-tolerated and safe. In both the effective and placebo groups, the frequency of treatment-emergent adverse reactions (TEAEs) was comparable, with disorientation being the most frequent TEAE. The majority of TEAEs below the 7.5% level were mild or moderate.

Vital signs, laboratory results, and ECG parameters in the active and placebo groups did not see any clinically meaningful alterations. The study’s safety results matched the recognized effectiveness and safety of ANAVEX®2-73. Additionally, safety and effectiveness were shown on the important and primary secondary goals.

Who Founded Anavex Life Sciences?

Who Founded Anavex Life Sciences?

Its main ingredient, ANAVEX2-73, is being researched for the treatment of Rett syndrome, Parkinson’s, Alzheimer’s, and other central nervous system disorders. The business’s headquarters are in New York, NY, and it was established on January 23, 2004, by Harvey Lalach and Athanasios Skarpelos.

Who Is On The Insider Roster For Anavex Life Sciences?

Athanasios Skarpelos, Elliot Favus, Peter D.O. Donhauser, & Sandra Boenisch are among Anavex Life Sciences’ insiders. Insiders own 11.00% of the outstanding shares of Anavex Life Sciences. Peter D.O. Donhauser ($25,690.55) was the insider who bought AVXL stock in the previous 24 months. Insiders have spent $25,690.55 on a total of 2,165 AVXL stock over the past 24 months.

Insiders Athanasios Skarpelos ($453,000.00), Elliot Favus ($3,538,530.00), & Sandra Boenisch ($4,422,444.88) sold AVXL stock in the previous 24 months. In the past 24 months, insiders have sold 507,196 Anavex Life Sciences stock for a total of $8,413,974.88.

Who Are The AVXL Shares’ Major Holders?

148 large shareholders and hedge funds hold stock of Anavex Life Sciences over the previous two years. BlackRock Inc. ($54.84M), State Street Corp. ($45.01M), Vanguard Group Inc. ($42.37M), Geode Capital Management LLC ($21.51M), Great Lakes Advisors LLC ($15.54M), Northern Trust Corp ($7.13M), as well as Charles Schwab Investment Management Inc. ($6.53M) were the institutional investors with the largest investments.

Institutional investors hold 31.93% of the shares in Anavex Life Sciences. In the past 24 months, investment banks have sold 4,799,474 shares in total. This share sale volume equates to roughly $65.67M in business. In the past 24 months, institutional investors have purchased a total of 13,536,628 shares. This volume of purchases entails roughly $213.76M in transactions.

Who Are Anavex Life Sciences Competitors?

avxl stock

Its main ingredient, ANAVEX2-73, is being researched for the treatment of Rett syndrome, Parkinson’s, Alzheimer’s, and other central nervous system disorders. The business’s headquarters are in New York, NY, and it was established on January 23, 2004, by Harvey Lalach and Athanasios Skarpelos.

The current consensus price objective for Exscientia is $15.67, suggests a significant upside of 155.16%. With a $54.00 consensus price objective, Anavex Life Sciences might increase by 348.13%. Analysts firmly feel Anavex Life Sciences is superior to Exscientia because to its higher consensus rating and greater potential upside

Compared to Exscientia, Anavex Life Sciences earns more money but generates less income. Exscientia and Anavex Life Sciences are currently selling at higher price-to-earnings ratios, indicating that Exscientia is currently the more expensive company.

Comparison Of Anavex Life Sciences And Exscientia

When compared users, Anavex Life Sciences scored 412 more votes for outperformance than Exscientia. Similar to how just 43.75% of users gave Exscientia an outstanding vote, 74.96% of users awarded Anavex Life Sciences an excellent vote.

Anavex Life Sciences saw 11 more media mentions than Exscientia in the previous week. 14 mentions of Anavex Life Sciences and 3 mentions of Exscientia were found. Anavex Life Sciences’ score of 0.62 was better than Exscientia’s average market sentiment polarity of 0.75, indicating that Exscientia is receiving more positive press than Anavex.

Institutional investors hold 27.8% of Exscientia’s stock. Comparatively, institutional investors hold 31.9% of the shares in Anavex Life Sciences. Insiders own 11.0% of the outstanding shares of Anavex Life Sciences. Solid organizational ownership is a sign that huge money managers, hedge funds, and endowments are bullish on a company’s long-term ability to outperform the market.

What Other Stocks Do Anavex Life Sciences Shareholders Own?

Inovio Pharmaceuticals (INO), POET Technologies (POETF), Brainstorm Cell Therapeutics (BCLI), LadRx (CYTR), Sanchez Energy (SN), Novavax (NVAX), Geron (GERN), VASCO Data Security International (VDSI), Sorrento Therapeutics (SRNE), and OPKO Health are a few of the companies that other Anavex Life Sciences investors own (OPK).

What Is The Current Stock Price Of Anavex Life Sciences?

Currently, the price of one shares of AVXL stock is around $12.05. On November 24, Anavex Life Sciences Corp. (NASDAQ:AVXL) released its earnings report. The biotechnology business met the average estimate of ($0.15) for the quarter’s earnings per share by reporting ($0.15).

The company generated ($0.10) EPS during the same time period the year before. The market value of Anavex Life Sciences (NASDAQ:AVXL) is $939.44 million. The biotechnology company’s annual net income (profit), calculated as ($0.62) per diluted share, is $-37,910,000.00.

The net income for Anavex Life Sciences (NASDAQ:AVXL) was -$37.91 million. Over the previous four quarters, AVXL’s earnings per share were -$0.62.

Invest In Anavex Life Sciences Stock Or Sell It?

Future AVXL stock forecast from Wall Street Stock Market & Finance report: Below, you will discover buy/sell signals, stock quotes, and AVXL stock forecast. The AVXL stock of Anavex Life Sciences and maybe its economic climate have been in a bearish cycle during the past 12 months, according to current data (if exists).

The NASDAQ ticker symbol for Anavex Life Sciences is “AVXL.” In the past year, Anavex Life Sciences has received “buy,” “hold,” & “sell” ratings from 2 Wall Street analysts. For the stock, there are now 2 buy ratings. Shareholders should “buy” AVXL stock, according to Wall Street experts.

Stocks in the health manufacturing sector(s) don’t seem to be extremely popular right now, according to a current trend. The future will likely show a positive trend, and our AI stock expert predicts that investing in AVXL stock could be profitable. We advise including this share in your portfolio because of its promising prospects.

What Is The Anticipated Stock Price For Anavex Life Sciences In 2023?

In Tuesday, February 7th 2023, the business is set to announce its upcoming quarterly earnings. The stock of Anavex Life Sciences has 2 12 month prices from analysts. Their predictions for the price of AVXL stock vary from $40.00 to $80.00.

They anticipate that during the next year, the company’s stock will rise to $54.00 on average. This represents a potential increase first from stock’s current market price of 348.1%.The consensus price objective among the 6 analysts who are providing 12-month price projections on Anavex Life Sciences Corp is 39.50, with high and low estimates of 80.00 and 16.00 respectively. From the previous price of 12.03, the median projection reflects a +228.35% rise.

Anavex Life Sciences Forecast 2025

The mean Anavex Life Sciences stock projection for 2025 is $6.09, with high predictions of $7.17 and low AVXL stock forecast of $5.27.

There are 12 AVXL stock forecast made for each month of 2025. The ordinary Anavex Life Sciences stock prediction for 2025 shows a decline from the most recent price of $15.3999996185303 of -60.48%.

Anavex Life Sciences Forecast 2027

Twelve AVXL stock forecast are made for each month of 2027 for the Anavex Life Sciences stock projection for 2027 (5 year), with an average AVXL stock forecast of $8.09, a high AVXL stock forecast of $10.65.

And a low AVXL stock forecast of $6.8. From the most recent price of $15.3999996185303, the mean AVXL stock forecast for 2027 represents a -47.46% decline.

Anavex Life Sciences Forecast 2030

The median AVXL stock forecast for 2030 is $3.44, with high predictions of $4.04 and low AVXL stock forecast of $2.67. There are 12 predictions made for each month of 2030.

According to the median Anavex Life Sciences stock estimate, the stock will cost $15.3999996185303 by 2030, which is a -77.65% decline.

Anavex Life Sciences Forecast 2032

One AVXL stock forecast is made for each month of 2032 for the Anavex Life Sciences stock projection for 2032 (10 years), with an average AVXL stock forecast of $6.41, a high prognosis of $6.41, and a low AVXL stock forecast of $6.41.

From the most recent price of $15.3999996185303, the average AVXL stock forecast 2032 shows a -58.36% decline.

Leave a Reply